News
The combination of antifibrotic therapy and pulmonary vasodilator therapy improved transplant-free survival but had no ...
Employers explore innovative strategies at the Greater Philadelphia Business Coalition on Health (GPBCH) Annual Conference, ...
Constance Blunt, MD, medical oncologist, Mary Bird Perkins Cancer Center, discusses some of the recent trends in cancer ...
The approval marks the second international approval for rozanolixizumab (Rystiggo; UCB Pharma) for generalized myasthenia ...
Sandeep Sahay, MD, FCCP, director of the Pulmonary Hypertension Program, Houston Methodist Hospital, previews key topics of ...
Mohit Narang, MD, explains why he switches patients with chronic lymphocytic leukemia (CLL) to the second-generation Bruton ...
Panelists discuss how the needs of older patients with spinal muscular atrophy (SMA) differ from infants, focusing on ...
Robert F. Kennedy Jr’s congressional hearing featured numerous statements from the secretary of HHS, including denouncing ...
Panelists discuss how spinal muscular atrophy (SMA) progresses over time, affecting motor function differently in older ...
The CDC uses molecular cluster detection to find the transmission of HIV that could pinpoint where there are gaps in HIV care ...
Two studies explored the quality-of-life impacts of lebrikizumab for atopic dermatitis, finding its benefits extend beyond ...
A significant number of patients taking Bruton tyrosine kinase inhibitors (BTKis) for chronic lymphocytic leukemia (CLL) develop atrial fibrillation (AF).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results